Phentolamine Infusion in Chronic Coronary Syndrome and Chronic Kidney Disease

Association of Periprocedural Phentolamine Infusion with Favorable Outcome in Patients with Chronic Kidney Disease and Chronic Coronary Syndrome undergoing coronary catheterization: A Prospective Randomized Controlled Study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202209493847741

Enrollment

107

Registered

2022-09-22

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease Cardiology

Interventions

Conventional strategy

Interventional strategy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic Kidney Disease Chronic Coronary Syndrome after a previous episode of Acute Coronary Syndrome including ST-segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), or unstable angina (UA), and planned for diagnostic coronary angiography or Percutaneous Coronary Intervention.

Exclusion criteria

Exclusion criteria: Normal kidney functions Single functioning kidney End-stage renal disease (ESRD) on regular dialysis History of kidney transplant Acute Kidney Injury triggered by cocaine, surgery, sepsis, trauma, or cardiogenic shock, pulmonary edema, acute heart failure with Left Ventricular Ejection Fraction <30%, systolic blood pressure <80 mmHg, bronchial asthma, multiple myeloma, pregnancy, allergy to phentolamine or Contrast Medium Received barbiturates, antipsychotic agents, phosphodiesterase-5 inhibitors, or Contrast Medium within 7 days of study entry Received a-adrenoreceptor blocker at the time of admission

Design outcomes

Primary

Measure	Time frame
Efficacy of periprocedural phentolamine infusion in improving the postprocedural urine output and prevention of Contrast-Induced Nephropathy-Acute Kidney Injury in Chronic Kidney Disease patients and lowering the incidence of Major Adverse Cardiac and Cerebrovascular Events within 90 days post-procedure.	—

Secondary

Measure	Time frame
Efficacy of periprocedural phentolamine infusion in reducing short-term all-cause morbidity following cardiac catheterization.	—

Countries

Egypt

Contacts

Public ContactKhaled Gabr

Associated colleague of critical care medicine

khaledgabr480@gmail.com0233025022

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 10, 2026